As of November 6, 2026, Akero Therapeutics, Inc. has Schedule 13D or 13G filings on record, none whose latest reports a stake of 5% or more. 11 filings are on record since August 12, 2025 (Schedule 13G/A, February 17, 2026).
Sell to companies like Akero Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Janus Henderson Group Plc · Percent: 4.1% · SCHEDULE 13G/A
- · Holder: RTW Investments, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Deep Track Capital, LP · Percent: 0% · SCHEDULE 13G/A
- · Holder: Wellington Management Group LLP · Percent: 0% · SCHEDULE 13G/A
- · Holder: T. Rowe Price Associates, Inc. · Percent: 4.8% · SCHEDULE 13G/A
Akero Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-12. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 4.8% | 3,810,076 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Janus Henderson Group Plc | 4.1% | 3,397,779 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Wellington Management Group LLP | 0% | 0 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| RTW Investments, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Deep Track Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Holding shares or following this stake? See who's behind Akero Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Akero Therapeutics, Inc. and the records around it.
Companies that share a holder
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Akero Therapeutics, Inc.
Get an email when Akero Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Akero Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Akero Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Akero Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Wellington Management Group LLP | 4.3% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 8.5% | SCHEDULE 13G/A |
| 2025-08-14 | RTW Investments, LP | 7.3% | SCHEDULE 13G/A |
| 2025-10-07 | Deep Track Capital, LP | 5.5% | SCHEDULE 13G |
| 2025-11-12 | Wellington Management Group LLP | 5.3% | SCHEDULE 13G |
| 2025-11-14 | T. Rowe Price Associates, Inc. | 4.8% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 7.9% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 0% | SCHEDULE 13G/A |
| 2026-02-13 | Deep Track Capital, LP | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Janus Henderson Group Plc | 4.1% | SCHEDULE 13G/A |
| 2026-02-17 | RTW Investments, LP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Akero Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.